0001209191-19-024503.txt : 20190412
0001209191-19-024503.hdr.sgml : 20190412
20190412171701
ACCESSION NUMBER: 0001209191-19-024503
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190401
FILED AS OF DATE: 20190412
DATE AS OF CHANGE: 20190412
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Galante Joseph C
CENTRAL INDEX KEY: 0001632384
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33637
FILM NUMBER: 19747034
MAIL ADDRESS:
STREET 1: 111 TENTH AVENUE
STREET 2: SUITE 200
CITY: NASHVILLE
STATE: TN
ZIP: 37203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001087294
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
BUSINESS ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE,
STATE: TN
ZIP: 37203
BUSINESS PHONE: 615-255-0068
MAIL ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE
STATE: TN
ZIP: 37203
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-04-01
0
0001087294
CUMBERLAND PHARMACEUTICALS INC
CPIX
0001632384
Galante Joseph C
2525 WEST END AVENUE
SUITE 950
NASHVILLE
TN
37203
1
0
0
0
Common Stock
2019-04-01
4
P
0
382
5.99
A
8732
D
Common Stock
2019-04-02
4
P
0
580
6.12
A
9312
D
Common Stock
2019-04-03
4
P
0
80
6.00
A
9392
D
Common Stock
2018-04-04
4
P
0
241
6.19
A
9633
D
Common Stock
2019-04-05
4
P
0
183
6.32
A
9816
D
Common Stock
2019-04-09
4
P
0
60
6.41
A
9876
D
The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019.
Joseph C. Galante by /s/ Michael Bonner as
attorney-in-fact
2019-04-12